AVX 13616 

AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug/ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.

955.06

C₅₀H₇₃Cl₂N₇O₇

900814-48-4

O=C(N[C@H](CCCCN)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(OCCC(C)C)=O)=O)=O)COC1=[C@@]([C@@]2=C(OCCC(C)C)C=CC3=C2C=CC=C3)C(C=CC=C4)=C4C=C1.Cl.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences